Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder

Journal of Cardiovascular Electrophysiology

Volumn 26, Issue 10, 2015, Pages 1039-1044

  Zhang, Claire ^a   Kutyifa, Valentina ^a   Moss, Arthur J ^a   McNitt, Scott ^a   Zareba, Wojciech ^a   Kaufman, Elizabeth S ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

adrenergic side effect; attention deficit hyperactivity disorder; congenital arrhythmia; long QT syndrome; stimulants

Indexed keywords

AMPHETAMINE; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANFACINE; LISDEXAMFETAMINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG THERAPY; FAINTNESS; FEMALE; FOLLOW UP; HEART ARREST; HEART BEAT; HEART RATE; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QTC INTERVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SUDDEN CARDIAC DEATH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE DRUG REACTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMORBIDITY; EPIDEMIOLOGY; MORTALITY; NEW YORK; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGISTER; SEX RATIO; SURVIVAL RATE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LONG QT SYNDROME; MALE; NEW YORK; PREVALENCE; PROGNOSIS; REGISTRIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL RATE; SYNCOPE; TREATMENT OUTCOME;

EID: 84945493519     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/jce.12739     Document Type: Article

References (46)

1. Goldenberg I, Moss AJ,: Long QT syndrome. J Am Coll Cardiol 2008; 51: 2291-2300.
2. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, Spazzolini C,: Prevalence of the congenital long-QT syndrome. Circulation 2009; 120: 1761-1767.
3. Moss AJ,: Long qt syndrome. JAMA 2003; 289: 2041-2044.
4. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr, Robinson J, Benhorin J, Choi S,. The long qt syndrome. Prospective longitudinal study of 328 families: Circulation 1991; 84: 1136-1155.
5. Martinez-Raga J, Knecht C, Szerman N, Martinez MI,: Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 2013; 27: 15-30.
6. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee Meeting, February 9 and 10, 2006 (http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202-00-TOC.htm) Accessed in 2014.
7. Wilens TE, Prince JB, Spencer TJ, Biederman J,: Stimulants and sudden death: What is a physician to do? Pediatrics 2006; 118: 1215-1219.
8. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE,: Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: Update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011; 50: 978-990.
9. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S,: Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127: 1102-1110.
10. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA,: ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365: 1896-1904.
11. Centers for Disease Control and Prevention. Mental health in the United States: Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder-United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 54: 842-847.
12. Bazett HC,: An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
13. Nissen SE,: ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-1448.
14. Perrin JM, Friedman RA, Knilans TK,: Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008; 122: 451-453.
15. Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T,: Efficacy and safety of OROS methylphenidate in adults with ADHD: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29: 239-247.
16. Rosler M, Fischer R, Ammer R, Ose C, Retz W,: A randomized, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with ADHD. Eur Arch Psychiatry Clin Neurosci 2009; 259: 120-129.
17. Bejerot S, Ryden EM, Arlinde CM,: Two-year outcome of treatment with central stimulant medication in adult ADHD: A prospective study. J Clin Psychiatry 2010; 71: 1590-1597.
18. Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE,: Short-term effects of lisdexamfetaminedimesy late on cardiovascular parameters in a 4-week clinical trial in adults with ADHD. J Clin Psychiatry 2009; 70: 1652-1661.
19. Wilens TE, Hammerness PG, Biederman JJ, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H,: Blood pressure changes associated with medication treatment of adults with ADHD. J Clin Psychiatry 2005; 66: 253-259.
20. Samuels JA, Franco K, Wan F, Sorof JM,: Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: A double-blind, randomized, cross-over trial. Pediatr Nephrol 2006: 21; 92-95.
21. Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG,: 24-hr ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 2002; 36: 1142-1149.
22. Findling RL, Short EJ, Manos MJ,: Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry 2001; 40: 525-529.
23. Young JL, Sarkis E, Qiao M, Wietecha L,: Once-daily treatment with atomoxetine in adults with ADHD: A 24-week randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011; 34: 51-60.
24. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J,: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-740.
25. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A,: Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007; 120: e1494-e1501.
26. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV,: ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2001; 306: 2673-2683.
27. Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC,: Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51: 147-156.
28. Rosero SZ, Zareba W, Moss AJ, Robinson JL, Hajj Ali RH, Locati EH, Benhorin J, Andrews ML,: Asthma and the risk of cardiac events in the long QT syndrome. Am J Cardiol 1999; 84: 1406-1411.
29. Thottathil P, Acharya J, Moss AJ, Jons C, McNitt S, Goldenberg I, Zareba W, Kaufman E, Qi M, Robinson JL,: Risk of cardiac events in patients with asthma and long QT syndrome treated with beta2 agonists. Am J Cardiol 2008; 102: 871-874.
30. Findlings RL, Biderman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, Tulloch SJ,: Short and long term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005; 147: 348-354.
31. Schwarts PJ, Locati EH, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R,: Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life threatening arrhythmias. Circulation 2001; 103: 89-95.
32. Seifi A, Griffith H, Avestimehr S, Dib H,: Atomoxetine-induced myocardial infarction. South Med J 2011; 104: 153-154.
33. Sawant S, Daviss SR,: Seizures and prolonged QTc with atomoxetine overdose. Am J Psychiatry 2004; 161: 757.
34. Kashani J, Ruha AM,: Isolated atomoxetine overdose resulting in seizure. J Emerg Med 2007; 32: 175-178.
35. Corman SL, Fedutes BA, Culley CM,: Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health-Sys-Pharm 2004; 61: 2391-2399.
36. Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M,: Cardiovascular safety of central nervous system stimulants in children and adolescents: Population based cohort study. BMJ 2012; 345: e4627.
37. Scherer D, Hassel D, Bloehs R, Zitron E, von Lowenstern K, Seyler C, Thomas D, Konrad F, Burgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP,: Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol 2009; 156: 226-236.
38. Seth R, Moss AJ, McNitt S, Zitron E, von Löwenstern K, Seyler C, Thomas D, Konrad F, Bürgers HF, Seemann G, Rottbauer W, Katus HA, Karle CA, Scholz EP,: Long QT syndrome and pregnancy. J Am Coll Cardiol 2007; 49: 1092-1098.
39. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D,: Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-1874.
40. Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S, Miyamoto Y, Goldenberg I, Andrews ML, McNitt S,: Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation 2007; 115: 2481-2489.
41. Roden DM., Clinical practice. Long-QT syndrome. N Engl J Med 2008; 358: 169-176.
42. Brenyo AJ, Huang DT, and, Aktas DT,: Congenital long and short QT syndromes. Cardiology 2012; 122: 237-247.
43. Moss AJ,: Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993; 72: 23B-25B.
44. Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Platonov PG, Priori SG, Qi M, Schwartz PJ, Shimizu W, Towbin JA, Vincent GM, Wilde AA, Zhang L,: Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011; 57: 51-59.
45. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ,: Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med 1998; 339: 960-965.
46. Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, Towbin JA, Robinson JL, Andrews ML, Napolitano C, Timothy K, Zhang L, Medina A,: Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol 2003; 42: 103-109.